Revert Project

🌟 Revert Project takes center stage at the 2nd Global Summit on #ArtificialIntelligence (GSAI) 🌍 On August 21, 2024, Professor Fiorella Guadagni, a renowned expert in Clinical Biochemistry and Molecular Biology from San Raffaele Roma Open University and coordinator of the #REVERT project, participated in the Global Summit on Artificial Intelligence 🌐 organised by Heighten Science Publications Prof. Guadagni delivered a compelling presentation titled: “#Clinician’s Trust in Advanced #AI Systems for Treatment Selection – The REVERT EU Project as a Paradigmatic Example.” She highlighted the transformative potential of Artificial Intelligence (#AI) and #MachineLearning (ML) in #healthcare 🏥, particularly in building clinicians’ trust in AI-based treatment selection systems. By showcasing the REVERT EU project as a case study, she illustrated how this initiative is pioneering new approaches to fostering confidence among medical professionals 🤝 through transparency and shared decision-making in AI-driven models. 🔍 The REVERT EU project’s innovative methodology leverages consensus among multiple AI algorithms to ensure that treatment recommendations are robust and reliable, thereby increasing clinician trust. As Professor Guadagni emphasized: 🗣️ "The key to widespread AI adoption in healthcare lies in creating systems where clinicians remain central to the decision-making process, while AI tools serve as supportive allies rather than opaque arbiters." #ColorectalCancer #HealthcareInnovation #coloncancer #mCRC #coloncancer #mCRC #Horizon2020🌐🔍 👉 For more information ⬇ https://lnkd.in/d3sKGkSw European Health and Digital Executive Agency (HaDEA) San Raffaele FONDAZIONE PTV POLICLINICO TOR VERGATA Instituto Murciano de Investigación Biosanitaria (IMIB) Fundación para la Formación e Investigación Sanitarias de la Región de Murcia UCAM Universidad Católica San Antonio de Murcia Malmö stad BioVariance GmbH ProMIS - Programma Mattone Internazionale Salute Bundesanstalt für Materialforschung und -prüfung IBBL (Integrated BioBank of Luxembourg) GenXPro GmbH Imago-Mol Cluster TRANSCEND - Regional Institute of Oncology Iasi

👥 A Fruitful Gathering to Finalize the Revert Project! 🤝 On July 24-25, the partners of the #REVERT project are meeting in Iasi, Romania 🇷🇴, for an important consortium meeting to optimally finalize the project, which will conclude in December 2024 with the organization of the final conference in #Brussels🎯   📅 On July 24 #REVERT partners met in the morning at the University House / Casa Universitarilor Universitatea „Alexandru Ioan Cuza” din Iași, where they had vibrant discussions on several key topics. They explored the preliminary results and debated on how to implement next steps, in particular on how to exploit the important project results. After a productive morning, partners explored the cultural richness of Iasi🏛️   📅 On July 25 the meeting concluded with a scientific tour showcasing some of Iasi's cutting-edge research facilities. 💱 These two days are not just about meetings but also about fostering collaboration, sharing knowledge, and driving innovation forward. The REVERT project is making significant strides in revolutionizing the treatment of advanced #colorectalcancer, and the collective efforts are paving the way for a brighter future in healthcare. 🌍🔬 🙏 Thanks to Imago-Mol Cluster and TRANSCEND - Regional Institute of Oncology Iasi for the organisation of the fruitful meeting! #REVERTProject #Innovation #Healthcare  #ColorectalCancer #Horizon2020 #CancerResearch #Health #mCRC #coloncancer #AI #ArtificialIntelligence 👩🔬🔬 European Health and Digital Executive Agency (HaDEA) San Raffaele FONDAZIONE PTV POLICLINICO TOR VERGATA Instituto Murciano de Investigación Biosanitaria (IMIB) Fundación para la Formación e Investigación Sanitarias de la Región de Murcia UCAM Universidad Católica San Antonio de Murcia Malmö stad BioVariance GmbH ProMIS - Programma Mattone Internazionale Salute Bundesanstalt für Materialforschung und -prüfung IBBL (Integrated BioBank of Luxembourg) GenXPro GmbH

📣📣📣 Exciting News! for the Revert Project 📣📣📣 🌟 #REVERT's groundbreaking AI-based oncology decision support system has been featured in Open Access Government! 📰✨ 👏 This recognition highlights the innovative work our consortium is doing to revolutionize treatment selection for #patients with unresectable metastatic #colorectal #cancer (#mCRC) through advanced #AI-based decision support systems (DSS) and driven technologies 🤖 🌐 The REVERT project brings together a dynamic consortium of 22 top-tier research #centers, #biobanks, #clinicalfacilities, and four #SMEs from five European countries 🇪🇺, all collaborating to create a multi-party AI-based system that generates a ranked list of treatment options for clinicians to consider. ☣ What makes the #REVERT DSS truly unique is its ability to generate a ranked list of treatment options for clinicians to consider. The system ensures #personalized #treatment #recommendations and promotes explainable AI for greater clinician trust 💡🔬 Read the full article to dive deeper into our journey toward transforming cancer care through AI. The future of #oncology decision support is here 👇 #ArtificialIntelligence #Oncology #Innovation #Healthcare #PersonalizedMedicine https://lnkd.in/dG6bqJwh European Health and Digital Executive Agency (HaDEA) San Raffaele FONDAZIONE PTV POLICLINICO TOR VERGATA Instituto Murciano de Investigación Biosanitaria (IMIB) Fundación para la Formación e Investigación Sanitarias de la Región de Murcia UCAM Universidad Católica San Antonio de Murcia Malmö stad BioVariance GmbH Imago-Mol Cluster TRANSCEND - Regional Institute of Oncology Iasi ProMIS - Programma Mattone Internazionale Salute Bundesanstalt für Materialforschung und -prüfung IBBL (Integrated BioBank of Luxembourg) GenXPro GmbH

The IBBL (Integrated BioBank of Luxembourg) within LIH has teamed up with the Europe-wide Revert Project to redefine colorectal #cancer therapy through the use of AI. 🤖 As part of this the IBBL will use its expertise in quality assurance and standardisation of processing methods to support the decision criteria for the performance of biomarkers associated with colorectal cancer (CRC). 🔎 Learn more: https://lnkd.in/eXe8BcmA

🌐 Exciting News for the Revert Project! 🇪🇺 CORDIS, the #EU #Research and #Innovation community platform, as part of the European Commission’s strategy for the dissemination and exploitation of research results of projects supported by EU funds, has recently published an article on the REVERT results. The recent article highlights the groundbreaking of REVERT in advancing #colorectal #cancer treatment. 🤖 By integrating predictive medicine and #AI, REVERT has developed an AI-based Decision Support System (DSS) to tailor the best treatment combinations for individual #patients with #metastatic #colorectal #cancer (#mCRC). 🩺 The DSS is currently undergoing in six medical oncology units across three European countries: Italy 🇮🇹, Spain 🇪🇸 and Romania 🇷🇴 📊 Colorectal cancer ranks high in cancer diagnoses and deaths in the EU. With mCRC having a challenging prognosis, REVERT's focus on unresectable cases is particularly significant. The project leverages diverse data sources, including clinical databases and UK Biobank datasets, adopting a personalized medicine approach. 🧬 Their innovative model of combinatorial therapy aims to identify the most efficient and cost-effective interventions for patients with unresectable mCRC. 🔍 The development of the REVERT database (RDB) on Amazon Web Services has paved the way for the DSS, currently in a clinical trial phase. Led by Prof. Mario Roselli at University Hospital #TorVergata, Italy, the study aims to individualize treatment for mCRC patients, determining optimal therapeutic options on a case-by-case basis. European Health and Digital Executive Agency (HaDEA) San Raffaele FONDAZIONE PTV POLICLINICO TOR VERGATA Instituto Murciano de Investigación Biosanitaria (IMIB) Fundación para la Formación e Investigación Sanitarias de la Región de Murcia UCAM Universidad Católica San Antonio de Murcia Malmö stad BioVariance GmbH Imago-Mol Cluster TRANSCEND - Regional Institute of Oncology Iasiși ProMIS - Programma Mattone Internazionale Salute Bundesanstalt für Materialforschung und -prüfung IBBL (Integrated BioBank of Luxembourg) GenXPro GmbH For more information follow the REVERT update! 👇 https://lnkd.in/dtNwzjUZ

🔬Exciting progress in #cancer research! Thanks to the work done by GenXPro GmbH, Revert Project is exploring the use of 🧬 RNA profiles to predict therapeutic responses and uncover novel treatment options. 🎉 #Colorectal #carcinoma (CRC) affects many lives in Europe, and standard treatments often involve #chemotherapy and targeted therapies. However, the lack of specific #biomarkers for targeted therapies leaves room for improvement in #patient specific decisions 🎗️ GenXPro GmbH is playing a crucial role, leveraging "MACE-Seq," a highly sensitive 3'mRNA method, to analyze degraded #RNA from #cancer tissues. The obtained RNA profiles are compared to public databases, incorporating therapeutically relevant information. Using #machinelearning and statistical approaches, @revert will generate a classifier-database to identify gene expression features responsible for drug sensitivity. Explore the details of this pioneering study ⬇ https://lnkd.in/dFi_iQY2 . 👩🔬🔬 #CancerResearch #PrecisionMedicine #Innovation #ColorectalCancer #REVERTProject

📺We are thrilled to share that the groundbreaking efforts of the Revert Project in the fight against colorectal cancer were recently showcased on PROTV, one of 🇷🇴 #Romania's leading media stations! 👩🔬 Prof. Cipriana Stefanescu, President of Imago-Mol Cluster’s Scientific Council and Scientific Coordinator alongside Prof. Adrian Iftene, #MedTech Coordinator and #IT Coordinator for IMAGO in Revert Project, had the honor of presenting our innovative project on a special 🇷🇴 Romanian TV show dedicated to the European Commission's support for #healthcare #research. 🚀 During the interview, they emphasized the vast consortium involved in #REVERT and delved into the challenges of merging diverse patient data to develop an #AI algorithm in order to revolutionize the treatment of colorectal cancer #patients through personalized medicine. 🌍 What makes this collaboration even more special? The spotlight on the North-East Regional Development Agency / Agentia pentru Dezvoltare Regionala Nord-Est (NERDA) and their crucial role in facilitating access for organizations from the North-East region to European consortia, as exemplified by the REVERT project. 🙏 It was an opportunity opportunity to share our progress and extend heartfelt thanks to PROTV for shining a light on our mission. Together, we're making strides toward a future where personalized treatments redefine the fight against colorectal cancer. #REVERTproject #ColorectalCancer #HealthcareInnovation #coloncancer 🌐🔍 For info ⬇ https://lnkd.in/dsDvwZpv

Last October UCAM Universidad Católica San Antonio de Murcia 🇪🇸 promoted the Revert Project during the Science and Technology Week of the Region of #Murcia! 🎙️ During the event Horacio Pérez-Sánchez was invited to the program Conciencia2, a podcast made live focused on #scientific dissemination of the radio station iRadio UCAM, to talk about his different researches and show how drug discovery can be applied in different diseases. During his talk he explained what the #Revert research was about, disclosed the project’s goal of finding possible drugs to help fight #colorectalcancer and shared with the audience different possible results. For more information see the project news ⬇ https://lnkd.in/dNENQVF3 #mCRC #Colon #Cancer #Coloncancer